COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX

被引：0
|
作者：
Waclawiczek, A. [1 ,2 ]
Leppa, A. [1 ,2 ]
Renders, S. [1 ,2 ,3 ]
Stumpf, K. [1 ,2 ]
Reyneri, C. [1 ,2 ]
Betz, B. [1 ,2 ]
Janssen, M. [3 ]
Shahswar, R. [4 ]
Donato, E. [1 ,2 ]
Unglaub, J. M. [3 ]
Schlenk, R. F. [3 ]
Hundemer, M. [3 ]
Pabst, C. [3 ]
Heuser, M. [4 ]
Raffel, S. [3 ]
Mueller-Tidow, C. [3 ]
Sauer, T. . [3 ]
Trumpp, A. [1 ,2 ]
机构：
[1] German Canc Res Ctr, Heidelberg, Germany
[2] HiSTEM GmbH, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Heidelberg, Germany
[4] Hannover Med Sch, Hannover, Germany
来源：
ANNALS OF HEMATOLOGY | 2023年 / 102卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
41
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [31] An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
    Al-Harbi, Sayer
    Hill, Brian T.
    Mazumder, Suparna
    Singh, Kamini
    DeVecchio, Jennifer
    Choudhary, Gaurav
    Rybicki, Lisa A.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Houghton, Janet A.
    Almasan, Alexandru
    BLOOD, 2011, 118 (13) : 3579 - 3590
  • [32] BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
    Pullarkat, Vinod A.
    Newman, Edward M.
    CANCER DISCOVERY, 2016, 6 (10) : 1082 - 1083
  • [33] The relationship between bcl-2 expression and response to chemotherapy in acute leukemia
    Maung, ZT
    Maclean, FR
    Reid, MM
    Pearson, ADJ
    Proctor, SJ
    Hamilton, PJ
    Hall, AG
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 115 - 121
  • [34] Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Pratz, Keith
    Potluri, Jalaja
    Pullarkat, Vinod
    Jonas, Brian A.
    Wei, Andrew H.
    Becker, Pamela S.
    Frankfurt, Olga
    Xu, Tu
    Hong, Wan-Jen
    Chyla, Brenda
    Pollyea, Daniel A.
    Letai, Anthony
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S201 - S201
  • [35] Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial
    Kytola, Sari
    Vaenttinen, Ida
    Ruokoranta, Tanja
    Partanen, Anu
    Holopainen, Annasofia
    Saad, Joseph
    Kuusisto, Milla E. L.
    Koskela, Sirpa
    Raty, Riikka
    Itala-Remes, Maija
    Vastrik, Imre
    Suvela, Minna
    Parsons, Alun
    Porkka, Kimmo
    Wennerberg, Krister
    Heckman, Caroline A.
    Jalkanen, Tero
    Huttunen, Teppo
    Ettala, Pia
    Rimpilainen, Johanna
    Siitonen, Timo
    Pyorala, Marja
    Kuusanmaki, Heikki
    Kontro, Mika
    BLOOD, 2025, 145 (04)
  • [36] Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia
    Gil, Kellen B.
    Abbott, Diana
    Amaya, Maria L.
    Schwartz, Marc
    Gutman, Jonathan A.
    Kent, Andrew
    Bosma, Grace
    Pollyea, Daniel A.
    McMahon, Christine M.
    LEUKEMIA & LYMPHOMA, 2024, 65 (14) : 2228 - 2230
  • [37] Role of bcl-2 family proteins in phorbol ester-induced apoptosis of acute myeloid leukemia cells
    Holbert, Cassandra
    Forrester, Jeffrey
    Roberts, Michael
    CANCER RESEARCH, 2016, 76
  • [38] Human A1 expression in acute myeloid leukemia and its relationship to bcl-2 expression
    Moreb, JS
    Zucali, J
    BLOOD, 2001, 97 (02) : 578 - 578
  • [39] Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond
    Choi, Jun H.
    Bogenberger, James M.
    Tibes, Raoul
    TARGETED ONCOLOGY, 2020, 15 (02) : 147 - 162
  • [40] Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond
    Jun H. Choi
    James M. Bogenberger
    Raoul Tibes
    Targeted Oncology, 2020, 15 : 147 - 162
12345